The Patient‑Derived Xenograft Model Market is emerging as an essential pillar in preclinical oncology research, providing more clinically relevant insights than traditional laboratory models. The Patient‑Derived Xenograft Model Market was valued at US$ 468.75 million in 2024 and is projected to reach US$ 1,119.36 million by 2031, exhibiting a compound annual growth rate (CAGR) of 13.5% during...
English
Arabic
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek